Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.
Biosimilars: Friend or Foe?
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.
The rapidly evolving UC market hots up with new competition in the biologics arena
In March 2006, Johnson & Johnson and Merck’s Remicade (infliximab) became the first biologic therapy approved to treat moderate to severe active UC in the European Union and provided physicians with a new treatment option to achieve disease remission and symptom control in the most severe patients.
However, it took more than six years for a second biologic agent to reach the market. AbbVie’s Humira (adalimumab) was approved in April 2012 and experienced strong uptake from launch, providing physicians with a subcutaneous alternative to Remicade’s IV route of administration.